Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001390478-26-000008
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $5,129 | $3,205 |
| General and administrative | 4,123 | 2,858 |
| Total operating expenses | 9,252 | 6,063 |
| Loss from operations | (9,252) | (6,063) |
| Non-operating income: | ||
| Interest income | 845 | 250 |
| Total non-operating income | 845 | 250 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is SELLAS Life Sciences Group, Inc.'s R&D?
- SELLAS Life Sciences Group, Inc. (SLS) reported R&D of $5.13M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s R&D changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s R&D increased by 60.0% year-over-year, from $3.21M to $5.13M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s R&D?
- Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s R&D has grown at a 0.6% compound annual growth rate (CAGR), from $15.67M to $16.02M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about SELLAS Life Sciences Group, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude